Previous studies suggest that central arginine vasopressin (AVP) signaling can inhibit the hypothalamic–pituitary–adrenal (HPA) axis. To test a role for the AVP V1A receptor in stress HPA axis ...

The trial is investigating the efficacy and safety of BH-200, a potent vasopressin V1b receptor ... which aims to address MDD in patients with HPA-axis dysfunction—a subgroup comprising ...

The double-blind trial is claimed to be the 'largest' precision psychiatry trial to assess a vasopressin V1b receptor ... needs of MDD patients with HPA-axis dysfunction. “The outcome of the ...

a potent vasopressin V1b receptor antagonist, for improved treatment of patients with MDD who have underlying HPA-axis (Hypothalamus‐pituitary‐adrenal axis) dysfunction. The neuropeptide ...

with particular reference to the molecular basis of the structural and functional diversity of receptors in the hypothalamo-pituitary-adrenal (HPA) axis and peripheral tissues such as the mammary ...

The group aimed to conduct a prospective study to evaluate the longitudinal relation among severe psychosocial stress, psychiatric morbidity, and HPA axis function in children who lost a parent in ...

Fowler and Sowerby1 stated that this therapy is not associated with hypothalamic–pituitary–adrenal (HPA) axis suppression. However, scenarios exist in which suppression may occur; therefore, some ...

“So, why were we required to test for possible HPA axis suppression in the first place?” Data derived from Bhatia N, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7997. According to ...